M&A boost as Johnson & Johnson bids for Actelion
Johnson & Johnson has offered Actelion a 23% premium on its shares in a $30bn all-cash bid, in what would be the largest European pharmaceuticals transaction in a decade. And with M&A activity strong during January, investment grade loan bankers are feeling more optimistic.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts